More on celiac disease as a model for schizophrenia.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to F C Dohan.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The use of a microcytotoxicity test for complement-dependent serum antibodies cytotoxic to cultured astrocytoma cells has been explored as an aid in the diagnosis of brain tumors. Fourteen of 21 randomly selected preoperative glioma patients (67%) had antibodies detectable by this assay in contrast to 4 of 21 normal blood donors (19%). Five of the glioma patients (24%) were strongly positive (cytotoxic index greater than 80-80) while none of the controls was in this range. Although positive responses were seen in patients with tumors of every grade, only 6 of 11 patients with astrocytomas of Grades I-III were positive as compared to 8 of 9 patients with Grade IV astrocytomas. The microcytotoxicity test used is simple, inexpensive and capable of being performed on an outpatient basis. It is concluded that this assay has usefulness both as a screening technique and as a diagnostic adjunct for patients suspected of having brain tumors.
The use of the blood-brain barrier and of tumor-specific antibodies to concentrate boron selectivity in gliomas for neutron capture therapy is considered experimentally and theoretically. The time-dependent concentration of two anionic boranes, B12 H11 SH2- and B12 H11 SOSB12 H114-, in the blood, brain, and tumor of rats bearing a tumor of gliomatous origin is reported. The rate of clearance of each anionic borane from the blood is correlated with the fraction of non-protein bound anion in the plasma. The use of antibodies to carry therapeutical useful amounts of boron to tumor-specific or tumor-associated antigens on the tumor cell surface will require different numbers of boron atoms bound per antibody depending on several immunological and physical parameters. Calculations using published values of antibody-antigen association constants and of cell surface antigen densities predict that in order to obtain 10mug 10B/g tumor from 10 to over 10,000 boron-10 atoms will have to be bound per tumor antigenic site.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.